Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities.
Michelle Winkler, PhD, MPH
Advertisement
Articles by Michelle Winkler, PhD, MPH
Advertisement
Latest Updated Articles
Rituximab Reference vs Biosimilar Utilization for Oncology vs Nononcology IndicationsPublished: November 9th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
4
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
5
